CMS Granted J-Codes for Chiesi Products – 1/9/24

Effective January 1, 2024 EFFECTIVE JANUARY 1, 2024 xxNEW J-Code: J2508xx Elfabrio is indicated for the treatment of adults with confirmed Fabry disease. Please see Important Safety Information below and Full Prescribing Information. xxNew J-Code: J0127x Lamzede is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients. Please […]

Sponsored Message: New FDA Approval in Locally Advanced/Metastatic Urothelial Cancer (mUC) – 1/3/24

Recent FDA Indication Approval in Locally Advanced/Metastatic Urothelial Cancer (mUC) Full Prescribing Information including BOXED WARNING NOW APPROVED! Now Approved in Combination With Pembrolizumab as a First-Line Treatment for Locally Advanced/ Metastatic Urothelial Cancer (mUC) Regardless of Cisplatin Eligibility Astellas Pharma Inc. and Seagen are pleased to announce the U.S. Food and Drug Administration (FDA) […]

KEYTRUDA(R) (pembrolizumab): New Indication – 12/21/23

 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ Learn more. Merck would like to inform you that the FDA has approved KEYTRUDA for the treatment of patients with resectable (tumors ≥4 cm or node positive) non–small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. • PD-L1 […]

Permanent J-Code for BARHEMSYS® (amisulpride injection): Available January 1, 2024 – 12/20/2

Effective for claims on or after January 1, 2024: J0184 Injection, amisulpride, 1 mg HCPCS Code Information1: HCPCS Code J0184 HCPCS Code Descriptor Injection, amisulpride, 1 mg WAC per HCPCS Unit $9.00 NDC Information2: NDC Number Package Description WAC per Package 71390-0125-21 One single-dose vial containing 5 mg/2 mL of intravenous solution* $45.00 71390-0125-20 Bundle […]